广东医学2024，Vol.45Issue(2)：171-176,6.DOI:10.13820/j.cnki.gdyx.20232416
基于PROISCD-GM(V1.0)慢性胃炎患者最小临床重要性差值的制定
Establishing minimum clinically important difference in patients with chronic gastritis based on the PROISCD-GM(V1.0)
摘要
Abstract
Objective To establish the Minimum Clinically Important Difference(MCID)for PROISCD-GM(V1.0)in patients with chronic gastritis.Methods Two cross-sectional surveys were conducted using PROISCD-GM(V1.0)and SF-36 before and after treatment.The MCID for each domain and the total score of the questionnaire were calculated using the anchor and distribution methods.The final MCID was obtained by combining the results from both methods.Results The difference in scores before and after treatment with PROISCD-GM(V1.0)for chronic gastritis was statistically significant(P＜0.001).The MCID for the dimensions of physical health,mental health,social health,spiritual/religious health,and the total score were 9.52,9.01,6.25,8.33,and 8.21 points,respectively.Conclusion When the score exceeds the MCID,it can be considered that the intervention measures have practical clinical signifi-cance.The established MCID can provide a basis for relevant clinical decisions and efficacy evaluation in the management of chronic gastritis.关键词
慢性胃炎/最小临床重要性差值/患者报告结局/疗效评价Key words
chronic gastritis/minimal clinically important difference/patient-reported outcomes/efficacy eval-uation分类
医药卫生引用本文复制引用
陈媛玲,李瑞雨,宋静,赵虎,缪秋菊,罗娜,陈莹..基于PROISCD-GM(V1.0)慢性胃炎患者最小临床重要性差值的制定[J].广东医学,2024,45(2):171-176,6.基金项目
国家自然科学基金资助项目(72164024),云南省教育厅公共卫生与疾病防控重点实验室重点课题(2023ZD10),云南省教育厅科学研究基金项目(2022J1535),云南省中青年学术和技术带头人后备人才项目(202305AC160046) （72164024）
